DeCiphering Systemic Diurnal MetabOlism and EnDocrinE Signaling in HEART Failure
CODE-HEART aims to uncover how heart failure alters systemic metabolic rhythms through interorgan communication, enhancing understanding of its complex multiorgan nature.
Projectdetails
Introduction
Heart failure (HF), the ultimate outcome of many cardiovascular pathologies, imposes a significant global health and economic burden while remaining associated with high mortality rates. There is therefore an urgent need for innovative approaches to comprehensively understand and treat HF.
Research Focus
Most HF research has thus far focused on the pathophysiology of the heart, only partially covering the role of non-cardiac organs, despite HF being a complex multiorgan syndrome. The extent to which extra-cardiac organs, particularly those playing a key role in metabolism control, contribute to HF remains largely unknown.
Project Aim
CODE-HEART aims to bridge this knowledge gap by focusing on metabolic interorgan mechanisms of disease. Our metabolism is temporally coordinated across tissues by the circadian clock system, which orchestrates a myriad of physiological and metabolic processes.
Preliminary Findings
My recent work has highlighted the significance of peripheral tissue-tissue communication for daily metabolic homeostasis. Notably, my preliminary findings suggest that when the heart is under stress, systemic glucose and lipid diurnal metabolism is rewired.
Hypothesis
In this project, I will test the hypothesis that the failing heart can alter systemic diurnal metabolic rhythms via the release of specific cardiac-secreted factors.
Methodology
To do so, I will:
- Determine the impact of HF on systemic metabolic rhythms and on the diurnal transcriptional landscape of liver, skeletal muscle, and white adipose tissue.
- Use specific knockout animal models to investigate the consequences of systemic metabolic rewiring on cardiac function in HF.
- Pinpoint the metabolic communication network between the heart, liver, and other metabolic tissues by labeling cardiomyocyte-specific secreted proteins and screening their functions in vitro and in vivo.
Conclusion
In summary, CODE-HEART will significantly advance our understanding of the metabolic and molecular adaptation occurring in HF.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.721.063 |
Totale projectbegroting | € 1.721.063 |
Tijdlijn
Startdatum | 1-1-2025 |
Einddatum | 31-12-2029 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- HUMANITAS UNIVERSITYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Linking Ketone Metabolism and Signaling in Heart Failure with Preserved Ejection FractionThis project aims to explore the dual role of ketones in heart failure with preserved ejection fraction, investigating their function as energy sources and protein modifiers to enhance cardiomyocyte health. | ERC Starting... | € 1.809.140 | 2023 | Details |
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart FailureDISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies. | ERC Consolid... | € 1.998.775 | 2022 | Details |
Circadian Control of Systemic Metabolism in Physiology and Type 2 DiabetesThis project aims to uncover how synchronizing energetic stressors with circadian rhythms can improve metabolism and inform new treatments for type 2 diabetes. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Circular RNAs to reverse pathological remodelling of the injured heartREVERSE aims to identify and validate therapeutic circular RNAs to target cardiac remodelling in chemotherapy-induced cardiotoxicity and SARS-CoV-2 infection, addressing unmet treatment needs. | ERC Advanced... | € 2.499.375 | 2022 | Details |
Linking Ketone Metabolism and Signaling in Heart Failure with Preserved Ejection Fraction
This project aims to explore the dual role of ketones in heart failure with preserved ejection fraction, investigating their function as energy sources and protein modifiers to enhance cardiomyocyte health.
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart Failure
DISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies.
Circadian Control of Systemic Metabolism in Physiology and Type 2 Diabetes
This project aims to uncover how synchronizing energetic stressors with circadian rhythms can improve metabolism and inform new treatments for type 2 diabetes.
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Circular RNAs to reverse pathological remodelling of the injured heart
REVERSE aims to identify and validate therapeutic circular RNAs to target cardiac remodelling in chemotherapy-induced cardiotoxicity and SARS-CoV-2 infection, addressing unmet treatment needs.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Boost of DiureticsHet project ontwikkelt een goedkope en effectieve methode voor thuismonitoring van hart- en longfalen, gericht op het tijdig signaleren van verslechtering om zorglasten te verlichten. | Mkb-innovati... | € 20.000 | 2020 | Details |
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair InterventionsCARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes. | EIC Pathfinder | € 4.349.410 | 2023 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients. | EIC Pathfinder | € 4.137.668 | 2023 | Details |
Boost of Diuretics
Het project ontwikkelt een goedkope en effectieve methode voor thuismonitoring van hart- en longfalen, gericht op het tijdig signaleren van verslechtering om zorglasten te verlichten.
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions
CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.
The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.